Pfizer and Valneva's Lyme disease bet rolls on to PhIII as more financing flows their way
Pfizer’s core focus on vaccine development extends well beyond the Covid-19 franchise. Their bet on a Lyme disease candidate out of Valneva is continuing to pump out positive data, pointing the partners toward a Phase III trial. And the French biotech is adding an additional $40 million in fresh debt financing from a pair of major players in the industry to help pay the freight for new development work.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.